Mustang Bio Inc (NASDAQ:MBIO) does about 28.90M shares in volume on a normal day but saw 2141514 shares change hands in the recent trading day. The company now has a market cap of 11.30M USD. Its current market price is $0.30, marking a decrease of -12.05% compared to the previous close of $0.35. The 52 week high reached by this stock is $3.39 whilst the lowest price level in 52 weeks is $0.13.
Mustang Bio Inc (MBIO) has a 20-day trading average at $0.3433 and the current price is -91.03% off the 52-week high compared with 137.00% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.4078 and its 200-day simple moving average is $0.8386. If we look at the stock’s price movements over the week, volatility stands at 11.39%, which increases to 11.75% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 40.84 to suggest the stock is neutral.
The consensus objective for the share price is $10.00, suggesting that the stock has a potential upside of 97.0% over the period.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 18, 2021 when BTIG Research initiated the stock to “Buy” and issued a price target of $11. Cantor Fitzgerald initiated its price target at $7.
The current price level is -12.09%, -24.91%, and -64.10% away from its SMA20, SMA50, and SMA200 respectively, with the MBIO price moving above the 50-day SMA on current market day. Mustang Bio Inc (MBIO) stock is down -19.38% over the week and -12.48% over the past month. Its price is -77.51% year-to-date and -89.64% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/31/2023, with the company’s earnings per share (EPS) of -2.06 above consensus estimates by 0.95. The company’s next earnings report forecasts estimating quarterly EPS at 0 and -3.25 for whole year.
To reach the target analysts have set, the stock logically needs to grow 97.0 percent from here.
Outstanding shares total 37.23M with insiders holding 7.56% of the shares and institutional holders owning 2.23% of the company’s common stock. The company has a return on equity of -1191.31%. The beta has a value of 1.97.
#####
